Trove Therapeutics’ lead biopharmaceutical product candidate is a proprietary preparation of recombinant human SCGB1A1 protein (rhSCGB1A1), which has potential clinical applications in a variety of respiratory diseases including persistent or chronic rhinosinusitis (CRS), acute lung injury due to severe influenza-like illness (ILI), smoke inhalation, sepsis or shock, and bronchiolitis obliterans. Recent discoveries also point toward its use in treating hematological malignancies. Trove has also created a next generation variant of rhSCGB1A1 protein that has significantly enhanced potency (rhSCGB1A1-HP) that enables its application in large chronic respiratory diseases (e.g. asthma, COPD) in an ambulatory setting.
A second secretoglobin (SCGB) protein product candidate, based on the recombinant human SCGB3A2 protein, has also completed non-clinical in vivo proof of concept studies in pulmonary fibrosis and lung cancer.